Audited Results 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ANG Lifesciences India Ltd reported a consolidated loss of ₹1,108.48 lakhs for FY26, improved from ₹1,241.33 lakhs loss in FY25. Revenue from operations was flat at ₹9,289.28 lakhs vs ₹9,284.66 lakhs year earlier. The company operates in pharmaceuticals and printing/packaging segments. The auditors issued an unmodified opinion but included an Emphasis of Matter highlighting: (1) HDFC Bank loan defaults of ₹2,586.45 lakhs (consolidated) where interest/instalments are overdue beyond 3-8 months, (2) non-deposit of statutory dues (ESI, PF, TDS) unpaid for over 6 months, (3) pending income tax disputes of ₹463.74 lakhs including ₹453.95 lakhs for Mansa Print, and (4) GST ITC reversal liability of ₹12.20 lakhs not regularized on GST portal. The company also has outstanding loans to subsidiary of ₹1,949.63 lakhs and guarantees of ₹1,242.28 lakhs.
The company remains loss-making with flat revenues and significant debt default issues. The Emphasis of Matter by auditors signals elevated liquidity risk and potential going concern concerns despite the unmodified audit opinion. Shareholders should monitor the company's ability to service HDFC Bank borrowings and resolve statutory dues.